Journal article
The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments
Abstract
High risk prostate cancer (HR-PrCa) is a subset of localized PrCa with significant potential for morbidity and mortality associated with disease recurrence and metastasis. Radiotherapy combined with Androgen Deprivation Therapy has been the standard of care for many years in HR-PrCa. In recent years, dose escalation, hypo-fractionation and high precision delivery with immobilization and image-guidance have substantially changed the face of …
Authors
Mesci A; Isfahanian N; Dayes I; Lukka H; Tsakiridis T
Journal
Clinical Genitourinary Cancer, Vol. 20, No. 1, pp. e25–e38
Publisher
Elsevier
Publication Date
February 2022
DOI
10.1016/j.clgc.2021.09.004
ISSN
1558-7673